Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models

Clinical Schizophrenia and Related Psychoses

Volumn 4, Issue 3, 2010, Pages 189-200

  Kantrowitz, Joshua T ^a,b   Javitt, Daniel C ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auditory; Glutamate; NMDA receptor; Review; Schizophrenia; Visual

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCYSTEINE; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCYLDODECLAMIDE; KETAMINE; LAMOTRIGINE; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; SARCOSINE; UNCLASSIFIED DRUG;

CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; EXCITOTOXICITY; GABAERGIC SYSTEM; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; MOLECULAR INTERACTION; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROCHEMISTRY; PHENOMENOLOGY; REVIEW; SCHIZOPHRENIA;

BRAIN; GLUTAMIC ACID; HUMANS; MODELS, CHEMICAL; MODELS, NEUROLOGICAL; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 77957674463     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.4.3.6     Document Type: Review

References (169)

1. Delay J, Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J Clin Exp Psychopathol 1955;16(2):104-112.
2. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188(4194):1217-1219.
3. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234(4783):1558-1563.
4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1(3):179-186. (Pubitemid 19126130)
5. Dingledine R, McBain CJ. Glutamate and aspartate. In: Siegel GJ, American Society for Neurochemistry, Albers RW, Brady S, Price DL, editors. Basic neurochemistry: molecular, cellular and medical aspects. 6th ed. Burlington (MA): Academic Press; 1999.
6. Kantrowitz JT, Javitt DC. Glutamatergic approaches to the conceptualization and treatment of schizophrenia. In: Javitt DC, Kantrowitz JT, editors. Handbook of neurochemistry and molecular neurobiology. 3rd ed. New York: Springer; 2009.
7. Carpenter WT, Bartko JJ, Strauss JS, Hawk AB. Signs and symptoms as predictors of outcome: a report from the International Pilot Study of Schizophrenia. Am J Psychiatry 1978;135(8):940-944.
8. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982;39(7):784-788.
9. Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: Livingston; 1919.
10. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry 1995;52(5):352-360.
11. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008;165(8):978-987.
12. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005;31(1):167-174.
13. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007;33(4):1013-1022. (Pubitemid 47216643)
14. Fenton WS, McGlashan TH. Antecedents, symptom progression, and longterm outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994;151(3):351-356.
15. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001;58(2):165-171. (Pubitemid 32142754)
16. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006;163(3): 418-425. (Pubitemid 44469383)
17. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 2007;33(5):1201-1212. (Pubitemid 47347909)
18. Lieberman JA. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry 2006;67(10):e14.
19. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000;157(4):549-559. (Pubitemid 30191193)
20. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta- analytic review. Am J Psychiatry 2008;165(5): 579-587.
21. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31(9):2033-2046.
22. Dickinson D, Ragland JD, Calkins ME, Gold JM, Gur RC. A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res 2006;85(1-3):20-29. (Pubitemid 44173013)
23. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48(7):618-624.
24. Hafner H, Maurer K, Trendler G, an der Heiden W, Schmidt M, Konnecke R. Schizophrenia and depression: challenging the paradigm of two separate diseases-a controlled study of schizophrenia, depression and healthy controls. Schizophr Res 2005;77(1):11-24.
25. Jones P, Rodgers B, Murray R, Marmot M. Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994;344(8934):1398-1402.
26. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002;159(7):1183-1189. (Pubitemid 34743259)
27. Ho BC, Andreasen NC, Nopoulos P, Fuller R, Arndt S, Cadoret RJ. Secondary prevention of schizophrenia: utility of standardized scholastic tests in early identification. Ann Clin Psychiatry 2005;17(1):11-18. (Pubitemid 40471679)
28. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 2006;59(9):863-871.
29. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, Schmeidler J, et al. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry 2005;62(12):1297-1304. (Pubitemid 41746607)
30. Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Kaplan Z, Knobler H, et al. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 2003;65(2-3):87-94. (Pubitemid 37434015)
31. Yamauchi K, Aki H, Tomotake M, Iga J, Numata S, Motoki I, et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin Neurosci 2008;62(4):404-411.
32. Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust N Z J Psychiatry 2008;42(6):496-504. (Pubitemid 351891128)
33. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 2003;1003:138-158. (Pubitemid 38083052)
34. Abi-Dargham A. Cortical dopamine in schizophrenia. In: Javitt DC, Kantrowitz JT, editors. Handbook of neurochemistry and molecular neurobiology. 3rd ed. New York: Springer; 2009.
35. Krystal JH, Perry EB Jr, Gueorgulieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005;62(9):985-994.
36. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. Model psychoses and schizophrenia. Am J Psychiatry 1962;119:61-67.
37. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148(10):1301-1308.
38. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51(3):199-214.
39. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13(1):9-19.
40. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000;57(12):1139-1147.
41. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25(4):455-467. (Pubitemid 32830950)
42. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997;17(3):141-150. (Pubitemid 27365955)
43. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52(12):998-1007.
44. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004;174(1):32-38. (Pubitemid 38925088)
45. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003;40(5):881-884. (Pubitemid 37522046)
46. Heresco-Levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs 2005;10(4):827-844. (Pubitemid 41659068)
47. Javitt DC. Phenomenology, aetiology and treatment of schizophrenia. Novartis Found Symp 2008;289:4-16;discussion 17-22, 87-93.
48. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005;38(6):301-311. (Pubitemid 41815687)
49. McGhie A, Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961;34:103-116.
50. Bowers MB Jr. Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry 1974;31(1):50-54.
51. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002;159(11):1944- 1946. (Pubitemid 35283267)
52. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 2009;66(6):533-539.
53. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999;33(6):523-533.
54. Ellison G, Keys A, Noguchi K. Long-term changes in brain following continuous phencyclidine administration: an autoradiographic study using flunitrazepam, ketanserin, mazindol, quinuclidinyl benzilate, piperidyl-3,4-3H(N)-TCP, and AMPA receptor ligands. Pharmacol Toxicol 1999;84(1):9-17. (Pubitemid 29069233)
55. Karadottir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005;438(7071):1162-1166. (Pubitemid 41831686)
56. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005;438(7071):1167-1171. (Pubitemid 41831687)
57. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281(5381):1349- 1352. (Pubitemid 28406826)
58. Homayoun H, Moghaddam B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent in- fluence and interaction with NMDA receptors. Cereb Cortex 2006;16(1):93-105. (Pubitemid 41748285)
59. Verkhratsky A, Kirchhoff F. NMDA Receptors in glia. Neuroscientist 2007;13(1):28-37.
60. Lindahl JS, Kjellsen BR, Tigert J, Miskimins R. In utero PCP exposure alters oligodendrocyte differentiation and myelination in developing rat frontal cortex. Brain Res 2008;1234:137-147.
61. Chen YJJ, Role LW, Talmage DA. Neuregulin 1 and schizophrenia. In: Javitt DC, Kantrowitz J, Lajtha A, editors. Handbook of neurochemistry and molecular neurobiology: schizophrenia. 3rd ed. New York: Springer; 2009.
62. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99(21):13675-13680. (Pubitemid 35215440)
63. Shinkai T, De Luca V, Hwang R, Muller DJ, Lanktree M, Zai G, et al. Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. Neuromolecular Med 2007;9(2):169-177. (Pubitemid 47065544)
64. Li D, He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 2007;175(2):917-922. (Pubitemid 46798286)
65. Shi J, Badner JA, Gershon ES, Liu C. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res 2008;98(1-3):89-97. (Pubitemid 350235905)
66. Maier W. Common risk genes for affective and schizophrenic psychoses. Eur Arch Psychiatry Clin Neurosci 2008;258 Suppl 2:37-40.
67. Talbot K, et al. Dysbindin-1 and its protein family. In: Javitt DC, Kantrowitz J, Lajtha A, editors. Handbook of neurochemistry and molecular neurobiology: schizophrenia. 3rd ed. New York: Springer; 2009.
68. Moghaddam B, Jackson ME. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci 2003;1003:131-137.
69. Weinberger DR. Genetic mechanisms of psychosis: in vivo and postmortem genomics. Clin Ther 2005;27 Suppl A:S8-15.
70. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10(1):40-68; image 5.
71. Mossner R, Schuhmacher A, Schulze-Rauschenbach S, Kuhn KU, Rujescu D, Rietschel M, et al. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. Eur Neuropsychopharmacol 2008;18(10):768-772.
72. Harrison PJ, Lyon L, Sartorius LJ, Buret PW, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008;22(3):308-322. (Pubitemid 351847454)
73. Ohtsuki T, Koga M, Ishiguro H, Horiuchi Y, Arai M, Niizato K, et al. A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr Res 2008;101(1-3):9-16.
74. Miyamoto E. Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci 2006;100(5):433-442. (Pubitemid 44609534)
75. Parwani A, Weiler MA, Blaxton TA, Warfel D, Hardin M, Frey K, et al. The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) 2005;183(3):265-274. (Pubitemid 41660411)
76. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004;29(1):208-218. (Pubitemid 38068031)
77. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP. Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 1998;19(5):434-444.
78. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20(2):106-118. (Pubitemid 29010370)
79. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005;30(3):633-639. (Pubitemid 40271165)
80. Hartvig P, Valtysson J, Lindner KJ, Kristensen J, Karlsten R, Gustafsson LL, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995;58(2):165-173.
81. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999;145(2):193-204. (Pubitemid 29362018)
82. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, et al., Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) 1998;135(3):213-229. (Pubitemid 28055456)
83. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 2000;47(2):137-143. (Pubitemid 30069737)
84. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000;22(3):293-302. (Pubitemid 30089540)
85. Passie T, Karst M, Wiese B, Emrich HM, Schneider U. Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology 2005;51(4):226-233. (Pubitemid 40976405)
86. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14(5):301-307. (Pubitemid 26151927)
87. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 1998;43(11): 811-816. (Pubitemid 28288379)
88. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000;57(3):270-276. (Pubitemid 30140436)
89. Ahn KH, Youn T, Cho SS, Ha TH, Ha KS, Kim MS, et al. N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process. Prog Neuropsychopharmacology Biol Psychiatry 2003;27(6):993-999. (Pubitemid 37141387)
90. Harborne GC, Watson FL, Healy DT, Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. Journal of Psychopharmacology 1996;10(2):134-140. (Pubitemid 26168448)
91. Hetem LA, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berl) 2000;152(3):283-288.
92. Honey RA, Turner DC, Honey GD, Sharar SR, Kumaran D, Pomarol-Clotet E, et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 2003;28(11):2037-2044. (Pubitemid 37412113)
93. Kieffaber PD, Kappenman ES, Bodkins M, Shekhar A, O'Donnell BF, Hetrick WP. Switch and maintenance of task set in schizophrenia. Schizophr Res 2006;84(2-3):345-358.
94. Wylie GR, Clark EA, Butler PD, Javitt DC. Schizophrenia patients show task switching deficits consistent with N-methyl-d-aspartate system dysfunction but not global executive deficits: implications for pathophysiology of executive dysfuntion in schizophrneia. Schizophr Bull 2010;36(3):585-594.
95. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999;156(10):1646-1649. (Pubitemid 29460002)
96. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 2005;77(1):43-58.
97. Sesack SR, Aoki C, Pickel VM. Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 1994;14(1):88-106.
98. Javitt DC, Liedeman E, Cienfuegos A, Shelley AM. Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull 1999;25(4):763-775. (Pubitemid 30013558)
99. Chang BP, Lenzenweger MF. Somatosensory processing and schizophrenia liability: proprioception, exteroceptive sensitivity, and graphesthesia performance in the biological relatives of schizophrenia patients. J Abnorm Psychol 2005;114(1):85-95.
100. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008;7(1):68-83.
101. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005;76(1):1-23.
102. Javitt DC. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol Neurootol 2000;5(3-4):207-215. (Pubitemid 30312189)
103. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D, et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 2009;158(2):705-712.
104. Javitt DC, Shelley A, Ritter W. Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clin Neurophysiol 2000;111(10):1733-1737.
105. Strous RD, Cowan N, Ritter W, Javitt DC. Auditory sensory ("echoic") memory dysfunction in schizophrenia. Am J Psychiatry 1995;152(10):1517-1519.
106. Brekke J, Kay DD, Lee KS, Green MF. Biosocial pathways to functional outcome in schizophrenia. Schizophr Res 2005;80(2-3):213-225. (Pubitemid 41713647)
107. Vidyasagar TR. A neuronal model of attentional spotlight: parietal guiding the temporal. Brain Res Brain Res Rev 1999;30(1):66-76.
108. Kwon YH, Nelson SB, Toth LJ, Sur M. Effect of stimulus contrast and size on NMDA receptor activity in cat lateral geniculate nucleus. J Neurophysiol 1992;68(1):182-196.
109. Schechter I, Butler PD, Zemon VM, Revheim N, Saperstein AM, Jalbrzikowski M, et al. Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. Clin Neurophysiol 2005;116(9):2204-2215. (Pubitemid 41262210)
110. Foxe JJ, Doniger GM, Javitt DC. Early visual processing deficits in schizophrenia: impaired P1 generation revealed by high-density electrical mapping. Neuroreport 2001;12(7):3815-3820.
111. Yeap S, Kelly SP, Sehatpour P, Magno E, Javitt DC, Garavan H, et al. Early visual sensory deficits as endophenotypes for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives. Arch Gen Psychiatry 2006;63(11):1180-1188. (Pubitemid 44708075)
112. Sergi MJ, Green MF. Social perception and early visual processing in schizophrenia. Schizophr Res 2003;59(2-3):233-241. (Pubitemid 35284697)
113. Revheim N, Butler PD, Schechter I, Jalbrzikowski M, Silipo G, Javitt DC. Reading impairment and visual processing deficits in schizophrenia. Schizophr Res 2006;87(1-3):238-245. (Pubitemid 44428135)
114. Doniger GM, Foxe JJ, Murray MM, Higgins BA, Javitt DC. Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. Arch Gen Psychiatry 2002;59(11):1011-1020.
115. Kim D, Wylie G, Pasternak R, Butler PD, Javitt DC. Magnocellular contributions to impaired motion processing in schizophrenia. Schizophr Res 2006;82(1):1-8. (Pubitemid 43202643)
116. Revheim N, Butler PD, Schechter I, Jalbrzikowski M, Silipo G, Javitt DC. Reading impairment and visual processing deficits in schizophrenia. Schizophr Res 2006;87(1-3):238-245. (Pubitemid 44428135)
117. Kantrowitz JT, Butler PD, Schecter I, Silipo G, Javitt DC. Seeing the world dimly: the impact of early visual deficits on visual experience in schizophrenia. Schizophr Bull 2009;35(6):1085-1094.
118. Kantrowitz JT, Rebheim N, Pasternak R, Silipo G, Javitt DC. It's all in the cards: effect of stimulus manipulation on Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res 2009;168(3):198-204.
119. Javitt DC. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol 2009;5:249-275.
120. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta- analysis. Q J Nucl Med 1998;42(3):211-221. (Pubitemid 28529874)
121. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000;48(7):627-640.
122. Balla A, Hashim A, Burch S, Javitt DC, Lajtha A, Sershen H. Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem Res 2001;26(8-9):1001-1006. (Pubitemid 33021426)
123. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 2001;25(2):157-164. (Pubitemid 32566337)
124. Balla A, Sershen H, Serra M, Koneru R, Javit DC. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 2003;28(1):34-44.
125. Javitt DC, Hashim A, Sershen H. Modulation of striatal dopamine release by glycine transport inhibitors. Neuropsychopharmacology 2005;30(4):649-656. (Pubitemid 40397071)
126. Carlsson ML. Are the disparate pharmacological profiles of competitive and un- competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (Hypothesis). J Neural Transm Gen Sect 1993;94(1):1-10.
127. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997;24(3):349-355.
128. Woo TU, Miller JL, Lewis DA. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 1997;154(7):1013-1015.
129. Reynolds GP, Beasley CL. GABAergic neuronal subtypes in the human frontal cortex--development and deficits in schizophrenia. J Chem Neuroanat 2001;22(1-2):95-100.
130. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005;57(3):252-260.
131. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006;63(10):1372-1376. (Pubitemid 44547546)
132. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 2004;174(1):143-150. (Pubitemid 38925099)
133. Balla A, Nattini ME, Sershen H, Lajtha A, Dunlop DS, Javitt DC. GABA(B)/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum. Neuropharmacology 2009;56(5):915-921.
134. Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 2006;19(2):151-157.
135. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004;29(2):300-307. (Pubitemid 38175148)
136. Contreras PC. D-serine antagonized phencyclidine- and MK-801-induced stereo-typed behavior and ataxia. Neuropharmacology 1990;29(3):291-293.
137. Linn GS, O'Keeffe RT, Lifshitz K, Schroeder C, Javitt DC. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology (Berl) 2007;192(1):27-38. (Pubitemid 46673898)
138. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, et al. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 2001;60(6):1414-1420. (Pubitemid 33144913)
139. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997;17(3):202-204. (Pubitemid 27365961)
140. Javitt DC, Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology (Berl) 1997;129(1): 96-98. (Pubitemid 27037457)
141. Sucher NJ, Lipton SA. Redox modulatory site of the NMDA receptor-channel complex: regulation by oxidized glutathione. J Neurosci Res 1991;30(3):582-591.
142. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, et al. Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation. Trends Neurosci 2002;25(9):474-480. (Pubitemid 35223002)
143. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12(10):3721-3728.
144. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 2008;3(4):e1944. (Pubitemid 352003354)
145. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006;22(1-2):83-93. (Pubitemid 41831607)
146. Steullet P, Neijt HC, Cuenod M, Do KQ. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006;137(3):807-819. (Pubitemid 43053945)
147. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17(8):2921-2927. (Pubitemid 27155025)
148. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004;174(1):39-44. (Pubitemid 38925089)
149. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human
150. Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007;62(7):739-746. (Pubitemid 47374648)
151. Rodriguez AL, Williams R. Recent progress in the development of allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 2007;10(6):715-722. (Pubitemid 350076392)
152. Robbins MJ, Starr KR, Honey A, Soffin EM, Rourke C, Jones GA, et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res 2007;1152:215-227. (Pubitemid 46823886)
153. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9(11):984-997, 979.
154. Olszewski RT, Wegorzewska MM, Monteiro AC, Krolikowski KA, Zhou J, Kozikowski AP, et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008;63(1):86-91. (Pubitemid 350234887)
155. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 2004;89(4):876-885. (Pubitemid 38684735)
156. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151(8):1234-1236. (Pubitemid 24240973)
157. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Ef- ficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56(1):29-36. (Pubitemid 29055047)
158. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 2001;4(4):385-391. (Pubitemid 33151682)
159. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004;55(2):165-171. (Pubitemid 38367720)
160. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44(11):1081-1089. (Pubitemid 28547143)
161. Heresco-Levy U, Javitt DC, Ebstein R, Bass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatmentrefractory schizophrenia. Biol Psychiatry 2005;57(6):577-585. (Pubitemid 40409697)
162. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2005;59(3):230-234.
163. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55(5): 452-456.
164. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai Ge. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005;62(11):1196-1204.
165. Kantrowitz JT, Malhotra AK, Cornblatt BA, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010;121(1-3):125-130.
166. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72(2-3):225-234. (Pubitemid 39550993)
167. Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008;63(1):6-8.
168. Woods SW, et al. Effects of oral glycine in the schizophrenia prodrome. Schizophr Res 2004;70(Suppl 1):79.
169. Buchanan RW, Javitt DC, Marder ST, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-1602.